share_log

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

Virpax Pharmaceuticals | 8-K: VIRPAX PHARMACEUTICALS REPORTS 2024 SECOND QUARTER RESULTS AND RECENT DEVELOPMENTS

Virpax製藥 | 8-K：VIRPAX PHARMICALS公佈2024年第二季度業績和近期進展
美股SEC公告 ·  2024/08/13 19:37

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals announced its Q2 2024 financial results, reporting an operating loss of $3.5M compared to $3.1M in Q2 2023. General and administrative expenses decreased to $1.5M from $1.9M, while R&D expenses increased to $2.0M from $1.3M YoY. The company ended the quarter with $1.9M in cash.The company reported positive results from its pharmacokinetics and safety study for Probudur, its lead pain relief asset, in a Swine Model pilot study. The study demonstrated well-tolerated results and a long-term, slow-release profile. Additionally, Virpax secured $2.8M through warrant exercises in July 2024 and regained Nasdaq minimum bid price compliance.In other developments, Virpax closed a $2.5M secured loan to settle litigation, subsequently repaid through warrant proceeds. The company's board was reorganized and reduced to seven members. The company also completed a $2.25M public offering in May 2024, issuing shares and warrants at $1.35 per unit.
Virpax Pharmaceuticals announced its Q2 2024 financial results, reporting an operating loss of $3.5M compared to $3.1M in Q2 2023. General and administrative expenses decreased to $1.5M from $1.9M, while R&D expenses increased to $2.0M from $1.3M YoY. The company ended the quarter with $1.9M in cash.The company reported positive results from its pharmacokinetics and safety study for Probudur, its lead pain relief asset, in a Swine Model pilot study. The study demonstrated well-tolerated results and a long-term, slow-release profile. Additionally, Virpax secured $2.8M through warrant exercises in July 2024 and regained Nasdaq minimum bid price compliance.In other developments, Virpax closed a $2.5M secured loan to settle litigation, subsequently repaid through warrant proceeds. The company's board was reorganized and reduced to seven members. The company also completed a $2.25M public offering in May 2024, issuing shares and warrants at $1.35 per unit.
Virpax製藥公司宣佈其2024年第二季度財務結果，報告運營損失爲350萬美金，而2023年第二季度爲310萬美金。一般和管理費用從190萬降至150萬，研發費用則從130萬增加至200萬。公司在本季度末現金餘額爲190萬美金。公司在其主要止痛藥物Probudur的藥代動力學和安全性研究中取得了積極結果，此研究是在豬模型的試點研究中進行的。研究顯示結果耐受良好，並具有長期緩釋特性。此外，Virpax在2024年7月通過行使Warrants籌集了280萬美金，並恢復了納斯達克最低買盤價格的合規性。在其他發展方面，Virpax關閉了一筆250萬美金的有擔保貸款以解決訴訟，隨後通過Warrants收益進行了償還。公司的董事會進行了重組，成員人數減少至七人。公司還在2024年5月完成了一項225萬美金的公開發行，以每單位1.35美金的價格發行股票和Warrants。
Virpax製藥公司宣佈其2024年第二季度財務結果，報告運營損失爲350萬美金，而2023年第二季度爲310萬美金。一般和管理費用從190萬降至150萬，研發費用則從130萬增加至200萬。公司在本季度末現金餘額爲190萬美金。公司在其主要止痛藥物Probudur的藥代動力學和安全性研究中取得了積極結果，此研究是在豬模型的試點研究中進行的。研究顯示結果耐受良好，並具有長期緩釋特性。此外，Virpax在2024年7月通過行使Warrants籌集了280萬美金，並恢復了納斯達克最低買盤價格的合規性。在其他發展方面，Virpax關閉了一筆250萬美金的有擔保貸款以解決訴訟，隨後通過Warrants收益進行了償還。公司的董事會進行了重組，成員人數減少至七人。公司還在2024年5月完成了一項225萬美金的公開發行，以每單位1.35美金的價格發行股票和Warrants。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Allogene Therapeutics
    ALLO
    -- 3.305
    Solid Biosciences
    SLDB
    -- 6.0010
    Pulmatrix
    PULM
    -- 10.060
    ABVC BioPharma
    ABVC
    -- 0.5402
    Fate Therapeutics
    FATE
    -- 1.665
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日